A Study of the Impact of Apremilast (CC-10004) on Quality of Life Efficacy and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

  • STATUS
    Recruiting
  • End date
    Nov 5, 2021
  • participants needed
    255
  • sponsor
    Amgen
Updated on 25 October 2020
cervical cap
cyclosporine
methotrexate
hormonal contraception
systemic therapy
option 2
cc-10004
puva
psoralen
apremilast
plaque psoriasis
acitretin
scalp psoriasis
nail psoriasis
palmoplantar psoriasis

Summary

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life.

Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in Western Europe. Subjects will be block-randomized equally to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). If subjects present with multiple manifestations, they will be allocated to the manifestation which is most severe, as determined by the subject.

However, all manifestations will be assessed for efficacy at each study visit.

Details
Treatment Placebo, Apremilast (CC-10004)
Clinical Study IdentifierNCT03774875
SponsorAmgen
Last Modified on25 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet